Recent Updates
Recently added Catalysts
CBLL Positive Sentiment Score: 65/100

Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference

Key Takeaway: Ceribell, Inc. will participate in the upcoming Bank of America Securities 2025 Health Care Conference, with CEO Jane Chao scheduled to present on May 14, 2025. The presentation aims to showcase Ceribell's advancements in medical technology, specifically its novel EEG platform for diagnosing neurological conditions. The company is focused on revolutionizing patient care with its proprietary system, which is already FDA cleared and utilized in critical care settings.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ceribell will present at a notable health care conference.
  • The presentation is led by the CEO, highlighting leadership involvement.
  • Ceribell has developed an innovative EEG platform for acute care.

Full Press Release Details

SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time.
Event: Bank of America Securities 2025 Health Care Conference
Date: Wednesday, May 14, 2025
Time: 10:55 a.m. PST / 1:55p.m. EST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Brian Johnston or Laine Morgan

Frequently Asked Questions

When is Ceribell's presentation at the health care conference?

Ceribell's presentation is on May 14, 2025, at 10:55 a.m. PST.

What is the main focus of CeriBell, Inc.?

Ceribell focuses on transforming the diagnosis and management of neurological conditions.

What is the Ceribell System designed for?

The Ceribell System is designed for rapid diagnosis and monitoring of neurological conditions.

Where can I watch the Ceribell presentation?

The presentation will be available in the 'Investor Relations' section of their website.

Is the Ceribell System FDA cleared?

Yes, the Ceribell System is FDA 510(k) cleared for suspected seizure activity.

Last updated: Apr 30, 2025